Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.

Age Diagnosis Epidemiology Multiple sclerosis Registry

Journal

Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039

Informations de publication

Date de publication:
02 Mar 2024
Historique:
received: 09 10 2023
revised: 25 02 2024
accepted: 29 02 2024
medline: 7 3 2024
pubmed: 7 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

The time to diagnosis of multiple sclerosis (MS) is of great importance for early treatment, thereby reducing the disability and burden of the disease. The purpose of this study was to determine the time from the onset of clinical symptoms to the diagnosis of MS and to evaluate the factors associated with a late diagnosis in Iranian MS patients. The present cross-sectional study was conducted on patients with MS who were registered in the National MS Registry System of Iran (NMSRI). Overall, 23291 MS patients registered in 18 provinces of Iran were included in this study. The mean (standard deviation) interval between the onset of the disease and diagnosis of MS was 13.42 (32.40) months, and the median was one month. The diagnostic interval of 41.6% of patients was less than one month, and 14.8% of them had a one-month time to diagnosis. Patients with an age of onset below 18 years and those diagnosed after the age of 50 years had a longer time to diagnosis (P<0.001). Patients with primary progressive MS (PPMS) had the longest time to diagnose and those with relapsing-remitting MS (RRMS) had the shortest time (P<0.001). The results of negative binominal regression showed that the average rate of delay in diagnosis in women was 12% less than that in men. The average delay in diagnosis in patients with a positive family history of MS was 23% more than that in others. The rate of delay in the diagnosis of patients with PPMS and secondary progressive MS was 2.22 and 1.66 times higher, respectively, compared with RRMS. The findings of the present study revealed that more than half of the MS patients were diagnosed within a one-month interval from the symptom onset, which is an acceptable period. More attention should be paid to patients' access to medical facilities and MS specialists.

Identifiants

pubmed: 38447483
pii: S0303-8467(24)00108-2
doi: 10.1016/j.clineuro.2024.108221
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108221

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Faezeh Khodaie (F)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Abdorreza Naser Moghadasi (AN)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Abolfazl Hosseinnataj (A)

Department of Biostatistics and Epidemiology, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.

Seyed Mohammad Baghbanian (SM)

Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.

Fereshteh Ashtari (F)

Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Nazanin Razazian (N)

Department of Neurology, School of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Maryam Poursadeghfard (M)

Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Nastaran Majdi-Nasab (N)

Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Hamidreza Hatamian (H)

Department of Neurology, School of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.

Samaneh Hoseini (S)

Department of Neurology, School of Medicine, Neurosciences Research Center, Aging Research Institute, Imam Reza Medical Research & Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Ali Nahayati (MA)

Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

Seyed Massood Nabavi (SM)

Department of Regenerative Medicine, Royan Institute for Stem Cell Technology and Biology, Tehran, Iran.

Fardin Faraji (F)

Department of Neurology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.

Mohammad Hossein Harirchian (MH)

Department of Neurology, School of Medicine, Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Nahid Hosseni Nejad Mir (NHN)

Department of Internal Medicine, School of Medicine, Shohadaye Ashayer Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran.

Nahid Beladi Moghadam (NB)

Department of Neurology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ehsan Sharifipour (E)

Department of Neurology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Asghar Bayati (A)

Department of Neurology, Shahrekord University of Medical Sciences and Health Services, Shahrekord, Iran.

Hoda Kamali (H)

Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Hossein Mozhdehipanah (H)

Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran.

Nazanin Jalali (N)

Department of Neurology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Marzieh Abotorabi-Zarchi (M)

Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Naser Kamyari (N)

Department of Biostatistics and Epidemiology, School of Health, Abadan University of Medical Sciences, Abadan, Iran.

Roya Nikbakht (R)

Department of Biostatistics and Epidemiology, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.

Amirreza Azimi (A)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Samira Navardi (S)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Hora Heidari (H)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Ali Sahraian (MA)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Sharareh Eskandarieh (S)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: sh_eskandarieh@yahoo.com.

Classifications MeSH